Top Markets
Coin of the day
Palvella Therapeutics, Inc. Palvella Therapeutics, Inc.

Palvella Therapeutics, Inc.

PVLA
Rang in aandelen #6138
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company... Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Aandeelprijs
$154.04
Marktkapitalisatie
$2.21B
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
172.88%
Land
US
Handel Palvella Therapeutics, Inc. (PVLA)

Categorie

Koersgeschiedenis voor Palvella Therapeutics, Inc. (PVLA)
Hoogste slotkoers: $151.69 op 2026-08-01

Laagste slotkoers: $13.11 op 2024-12-01
Koersgeschiedenis van Palvella Therapeutics, Inc. van 2024 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 7.48%
2025 649.84%
2024 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$547.65 40.75%
US
$1.06K 49.04%
NL
$122.63 -12.65%
AU
$143.63 472.23%
US
$765.25 7.19%
CH